Abstract
Corporal tissue fibrosis is critical in diabetes-associated erectile dysfunction. Transforming growth factor-β1/Small mothers against decapentaplegic-2 (TGF-β1/Smad2) contributes to the induction of fibrosis in corporal tissue. Smad7 is accepted as a general negative regulator of Smad signaling, although its role in corporal fibrosis is unknown. Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid used for biliary and liver related disorders and has antifibrotic effects in the liver. This study investigated the effects of UDCA on diabetic erectile dysfunction. Forty-eight male Spraque Dawley rats were divided into six groups: nondiabetic (n = 6), nondiabetic+20 mg/kg UDCA (n = 6), nondiabetic+80 mg/kg UDCA (n = 6), diabetic (n = 10), diabetic+20 mg/kg UDCA (n = 10), diabetic+80 mg/kg UDCA (n = 10). Diabetes was induced by intraperitoneal injection of 60 mg/kg Streptozocin. UDCA (20 and 80 mg/kg/day) or saline was subsequently administered via oral gavage for 56 days. Erectile function was evaluated as measurement of maximum intracavernosal pressure (m-ICP)/mean arterial pressure (MAP) and total ICP/MAP. Corporal tissues were evaluated by Western blotting and Masson’s trichrome staining. Electrical stimulation-induced m-ICP/MAP responses were higher in UDCA-treated diabetic rats compared to untreated diabetic rats, respectively (20 mg/kg; 4 V: 0.77 ± 0.11 vs 0.45 ± 0.09, p = 0.0001 and 80 mg/kg; 4 V: 0.78 ± 0.11 vs 0.45 ± 0.09, p = 0.0001) UDCA prevented the increase in phospho-Smad2 and fibronectin protein expressions in diabetic corporal tissue both at 20 mg/kg (p = 0.0002, p = 0.002 respectively) and 80 mg/kg doses (p < 0.0001 for both). Smad7 protein expressions were significantly increased in the UDCA-treated diabetic groups compared to the untreated diabetic group (20 mg/kg: p = 0.0079; 80 mg/kg: p = 0.004). Furthermore, UDCA significantly prevented diabetes-induced increase in collagen (20 mg/kg: p = 0.0172; 80 mg/kg: p = 0.0003) and smooth muscle loss (20 mg/kg: p = 0.044; 80 mg/kg: p = 0.039). In conclusion, UDCA has a potential protective effect on erectile function in diabetic rats by altering fibrotic pathways via inhibition of TGF-β1/Smad2 and activation of Smad7.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Maseroli E, Corona G, Rastrelli G, Lotti F, Cipriani S, Forti G, et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. 2015;12:956–65.
Kouidrat Y, Pizzol D, Cosco T, Thompson T, Carnaghi M, Bertoldo A, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017;34:1185–92.
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460–3.
Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17:39–57. https://doi.org/10.1038/sj.ijir.3901250.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.
Kovanecz I, Nolazco G, Ferrini MG, Toblli JE, Heydarkhan S, Vernet D, et al. Early onset of fibrosis within the arterial media in a rat model of type 2 diabetes mellitus with erectile dysfunction. BJU Int. 2009;103:1396–404.
Zhang LW, Piao S, Choi MJ, Shin HY, Jin HR, Kim WJ, et al. Role of increased penile expression of transforming growth factor-beta1 and activation of the smad signaling pathway in erectile dysfunction in streptozotocin-induced diabetic rats. J Sex Med. 2008;5:2318–29.
Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell. 1997;89:1165–73.
Zhu HJ, Iaria J, Sizeland AM. Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J. Biol. Chem. 1999;274:258–64.
Yan X, Liao H, Cheng M, Shi X, Lin X, Feng XH, et al. Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transforming Growth Factor-β (TGF-β)/Smad Signaling. J Biol Chem. 2016;291:382–92.
Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 1999;397:710–3.
Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev. 2000;14:187–97.
Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol. 2002;13:1464–72.
Dooley S, Hamzavi J, Breitkopf K, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology. 2003;125:178–91.
Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol. 2004;25:513–7.
Wang W, Huang XR, Li AG, Liu F, Li JH, Truong LD, et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol. 2005;16:1371–83.
He W, Li AG, Wang D, Han S, Zheng B, Goumans MJ, et al. Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. EMBO J. 2002;21:2580–90.
Liu X, Lee J, Cooley M, Bhogte E, Hartley S, Glick A. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res. 2003;63:7760–8.
Wang B, Omar A, Angelovska T, Drobic V, Rattan SG, Jones SC, et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol. 2007;293:H1282–90.
Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC, et al. Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol. 2005;96:368–73.
Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res. 2007;67:2317–24.
Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 2001;276:17058–62.
Verrecchia F, Vindevoghel L, Lechleider RJ, Uitto J, Roberts AB, Mauviel A. Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner. Oncogene. 2001;20:3332–40.
Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int. 2002;62:1149–59.
Hocevar BA, Brown TL, Howe PH. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 1999;18:1345–56.
Zhou F, Li GY, Gao ZZ, Liu J, Liu T, Li WR, et al. The tgf-beta1/smad/ctgf pathway and corpus cavernosum fibrous-muscular alterations in rats with streptozotocin-induced diabetes. J Androl. 2012;33:651–9.
Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res. 2002;14:466–71. https://doi.org/10.1038/sj.ijir.3900910.
Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA Guideline. J Urol. 2018;200:633–41.
Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020;72:1145–51.
El-Sakka AI. Reversion of penile fibrosis: current information and a new horizon. Arab J Urol. 2011;9:49–55.
El-Sakka AI, Yassin AA. Amelioration of penile fibrosis: Myth or reality. J Androl. 2010;31:324–35.
Keith BD. Ursodeoxycholic acid to inhibit the growth of hepatic metastases. Med Hypotheses. 2000;55:379–82.
Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res. 2008;38:123–31.
Pathil A, Mueller J, Ludwig JM, Wang J, Warth A, Chamulitrat W, et al. Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of tgf-beta1/smad2/3 signalling. Br J Pharmacol. 2014;171:5113–26.
Liang TJ, Yuan JH, Tan YR, Ren WH, Han GQ, Zhang J, et al. Effect of ursodeoxycholic acid on tgf beta1/smad signaling pathway in rat hepatic stellate cells. Chin Med J. 2009;122:1209–13.
Li X, Han KQ, Shi YN, Men SZ, Li S, Sun MH, et al. [effects and mechanisms of ursodeoxycholic acid on isoprenaline-induced myocardial fibrosis in mice]. Zhonghua Yi Xue Za Zhi. 2017;97:387–91.
Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal research: explanation and elaboration for the arrive guidelines 2.0. PLoS Biol. 2020;18:e3000411.
Qabazard B, Yousif M, Mousa A, Phillips OA. GYY4137 attenuates functional impairment of corpus cavernosum and reduces fibrosis in rats with STZ-induced diabetes by inhibiting the TGF-β1/Smad/CTGF pathway. Biomed Pharmacother. 2021;138:111486.
Etuk EU. Animals models for studying diabetes mellitus. Agric Biol J North Am. 2010;1:130–4.
Buko VU, Kuzmitskaya-Nikolaeva IA, Naruta EE, Lukivskaya OY, Kirko SN, Tauschel HD. Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet. Hepatol Res. 2011;41:647–59.
Buko VU, Lukivskaya OY, Naruta EE, Belonovskaya EB, Tauschel HD. Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis. J Clin Exp Hepatol. 2014;4:293–301.
Quinlan DM, Nelson RJ, Partin AW, Mostwin JL, Walsh PC. The rat as a model for the study of penile erection. J Urol. 1989;141:656–61.
Rehman J, Christ G, Melman A, Fleischmann J. Intracavernous pressure responses to physical and electrical stimulation of the cavernous nerve in rats. Urology. 1998;51:640–4.
Yilmaz-Oral D, Onder A, Kaya-Sezginer E, Oztekin CV, Zor M, Gur S. Restorative effects of red onion (Allium cepa L.) juice on erectile function after-treatment with 5α-reductase inhibitor in rats. Int J Impot Res. 2022;34:269–76. https://doi.org/10.1038/s41443-021-00421-y.
Sezen SF, Burnett AL. Intracavernosal pressure monitoring in mice: responses to electrical stimulation of the cavernous nerve and to intracavernosal drug administration. J Androl. 2000;21:311.
Hannan JL, Kutlu O, Stopak BL, Liu X, Castiglione F, Hedlund P, et al. Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats. J Sex Med. 2014;11:1442–51.
Kamshoushi ASN, Helal S, Hassaan P, Omar H. A study of the correlation between angiotensin (1-7) and the histopathological changes in the penises of experimentally diabetic rats. Open J Endocr Metab Dis. 2018;8:81–92.
Abraham-Juárez MJ. Western blot in maize. Bio-protoc. 2019;101:e3257.
Zhou F, Xin H, Liu T, Li GY, Gao ZZ, Liu J, et al. Effects of icariside II on improving erectile function in rats with streptozotocin-induced diabetes. J Androl. 2012;33:832–44.
Barut EN, Engin S, Yasar YK, Sezen SF. Riluzole, a neuroprotective agent, preserves erectile function following bilateral cavernous nerve injury in male rats. Int J Impot Res. https://doi.org/10.1038/s41443-023-00680-x. Epub ahead of print (2023).
Hatzimouratidis K, Hatzichristou D. How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. Curr Diab Rep. 2014;14:545.
Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications. 2011;25:129–36.
Ruan Y, Li M, Wang T, Yang J, Rao K, Wang S, et al. Taurine supplementation improves erectile function in rats with streptozotocin-induced type 1 diabetes via amelioration of penile fibrosis and endothelial dysfunction. J Sex Med. 2016;13:778–85.
Yuan P, Ma D, Gao X, Wang J, Li R, Liu Z, et al. Liraglutide ameliorates erectile dysfunction via regulating oxidative stress, the rhoa/rock pathway and autophagy in diabetes mellitus. Front Pharmacol. 2020;11:1257.
Cui K, Tang Z, Li CC, Wang T, Rao K, Wang SG, et al. Lipoxin a4 improves erectile dysfunction in rats with type i diabetes by inhibiting oxidative stress and corporal fibrosis. Asian J Androl. 2018;20:166–72.
Christ GJ, Hsieh Y, Zhao W, Schenk G, Venkateswarlu K, Wang HZ, et al. Effects of streptozotocin-induced diabetes on bladder and erectile (dys)function in the same rat in vivo. BJU Int. 2006;97:1076–82.
Winston JA, Rivera A, Cai J, Patterson AD, Theriot CM. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16:e0246161.
Oh AR, Bae JS, Lee J, Shin E, Oh BC, Park SC, et al. Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice. BMB Rep. 2016;49:105–10.
Troisi G, Crisciotti F, Gianturco V, D’Ottavio E, Lo Iacono C, Formosa V, et al. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case control study. Clin Ter. 2013;164:203–7.
Floreani A, Cazzagon N, Franceschet I, Canesso F, Salmaso L, Baldo V. Metabolic syndrome associated with primary biliary cirrhosis. J Clin Gastroenterol. 2015;49:57–60.
Murakami M, Une N, Nishizawa M, Suzuki S, Ito H, Horiuchi T. Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. Springerplus. 2013;2:20.
Bomzon A, Ljubuncic P. Bile acids as endogenous vasodilators? Biochem Pharmacol. 1995;49:581–9.
Fiorucci S, Zampella A, Cirino G, Bucci M, Distrutti E. Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: Role of gaseous mediators. Am J Physiol Heart Circ Physiol. 2017;312:H21–32.
Sinisalo J, Vanhanen H, Pajunen P, Vapaatalo H, Nieminen MS. Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. Br J Clin Pharmacol. 1999;47:661–5.
Sunagane N, Kobori T, Urono T, Kubota K. Possible mechanisms of spasmolytic action of bile salts on the isolated guinea-pig gallbladder. Nihon Heikatsukin Gakkai Zasshi. 1990;26:143–50.
Ko SH, Hong OK, Kim JW, Ahn YB, Song KH, Cha BY, et al. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem. 2006;98:343–55.
Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol. 2000;157:1353–63.
Li JH, Wang W, Huang XR, Oldfield M, Schmidt AM, Cooper ME, et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGEERK1/2 MAP kinase signaling pathway. Am J Pathol. 2004;164:1389–97.
Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, et al. Advanced glycation end products cause epithelialmyofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Investig. 2001;108:1853–63.
Martinez N, Vallerskog T, West K, Nunes-Alves C, Lee J, Martens GW, et al. Chromatin decondensation and T cell hyperresponsiveness in diabetes-associated hyperglycemia. J Immunol. 2014;193:4457–68.
Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol. 2007;13:3056–62.
Tao M, Tasdemir C, Tasdemir S, Shahabi A, Liu G. Penile alterations at early stage of type 1 diabetes in rats. Int Braz J Urol. 2017;43:753–61.
Chen Y, Zhou B, Yu Z, Yuan P, Sun T, Gong J, et al. Baicalein Alleviates Erectile Dysfunction Associated With Streptozotocin-Induced Type I Diabetes by Ameliorating Endothelial Nitric Oxide Synthase Dysfunction, Inhibiting Oxidative Stress and Fibrosis. J Sex Med. 2020;17:1434–47.
Wu Z, Wang H, Ni F, Jiang X, Xu Z, Liu C, et al. Islet transplantation improved penile tissue fibrosis in a rat model of type 1 diabetes. BMC Endocr Disord. 2018;18:49.
Ismail EA, Younis SE, Ismail IY, El-Wazir YM, El-Sakka AI. Early administration of phosphodiesterase 5 inhibitors after induction of diabetes in a rat model may prevent erectile dysfunction. Andrology. 2020;8:241–8.
Francis SH, Corbin JD. PDE5 inhibitors: targeting erectile dysfunction in diabetics. Curr Opin Pharmacol. 2011;11:683–8.
Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharm. Rev. 2011;63:811–59.
Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. New Engl J Med. 1989;320:1025–30.
Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY. Disruption of the smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (uuo) in mice. Nephrol Dial Transplant. 2009;24:1443–54.
Liu GX, Li YQ, Huang XR, Wei L, Chen HY, Shi YJ, et al. Disruption of smad7 promotes ang ii-mediated renal inflammation and fibrosis via sp1-tgf-beta/smad3-nf.Kappab-dependent mechanisms in mice. PLoS One. 2013;8:e53573.
Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, et al. Inhibition of renal fibrosis by gene transfer of inducible smad7 using ultrasound-microbubble system in rat uuo model. J Am Soc Nephrol. 2003;14:1535–48.
Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, et al. Hepatocyte-Specific Smad7 Expression Attenuates TGFb-Mediated Fibrogenesis and Protects Against Liver Damage. Gastroenterology. 2008;135:642–659.e46.
Hamzavi J, Ehnert S, Godoy P, Ciuclan L, Weng H, Mertens PR, et al. Disruption of the Smad7 gene enhances CCI4-dependent liver damage and fibrogenesis in mice. J Cell Mol Med. 2008;12:2130–44.
Acknowledgements
The authors would like to acknowledge Feride Sena Sezen’s contribution to the experimental methodology, Yesim Kaya Yasar’s contribution to the analysis of the data, Atlas Biotechnology Laboratory’s (Ankara, Türkiye) contribution to the analysis of Western Blot, Scientific Research Project Coordination Unit of Karadeniz Technical University for funding and KTU Academic Writing Center for checking the English linguistics of the article.
Funding
This study was supported by the Scientific Research Project Coordination Unit of Karadeniz Technical University (Grant Number: TDK-2020-8748) and presented as a part of doctoral thesis.
Author information
Authors and Affiliations
Contributions
Conceptualization: ICN, NIK. Methodology: ICN, SS, GK, NIK. Data curation, investigaton: ICN, SS, GK, MKD, NIK. Funding acquisition: NIK. Writing original draft: ICN, NIK. Review & editing: ICN, SS, MKD, NIK.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cavusoglu Nalbantoglu, I., Sevgi, S., Kerimoglu, G. et al. Ursodeoxycholic acid ameliorates erectile dysfunction and corporal fibrosis in diabetic rats by inhibiting the TGF-β1/Smad2 pathway. Int J Impot Res (2024). https://doi.org/10.1038/s41443-024-00868-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41443-024-00868-9